Amvuttra
Productby Alnylam Pharmaceuticals
Heard in 3 episodes across 2 shows since Oct 2026
Amvuttra is a prescription medicine developed by Alnylam Pharmaceuticals for treating transthyretin-mediated amyloidosis, including cardiomyopathy associated with ATTR-CM.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Amvuttra per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Oct 30 | 0.01‰ | 1 |
| Nov 13 | 0.03‰ | 4 |
Email alert
Email me when Amvuttra comes up on a podcast
One email a week at most, with the new episodes that mention Amvuttra. Free, no account needed, unsubscribe in one click.
What experts have said about Amvuttra
3 statements · 1 positive · 2 negative
Alnylam is struggling to increase Amvuttra prescriptions
“Alnylam is struggling with getting more prescriptions.”
Open the episode · 421: The future of heart drug research in the wake of study setbacksListen at 8:09
Amvuttra is a blockbuster drug
“Amputra is a blockbuster drug.”
Open the episode · 421: The future of heart drug research in the wake of study setbacksListen at 8:14
Alnylam’s Amvuttra launch has slowed below expectations.
“The Almalum launch with Ambutra has kind of petered out”
Open the episode · Episode 203 - November 13, 2026Listen at 27:11
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring Amvuttra, newest first